The changing face of chronic HBV infection. The Italian Master-B cohort

AUTORI:
G. Brancaccio on behalf of the Master-B Study Group

AFFILIAZIONI:
Infectious Diseases, Second University of Naples;

Aim: Chronic HBV infection is still a major health problem in Europe, intensified by increasing immigration from endemic areas. The Master-B study was aimed at defining the current profile of chronic HBV-infected individuals and their long-term clinical outcome.

Methods: Consecutive HBsAg-positive patients seen in 75 Italian specialized centers were enrolled from June 2009 to December 2011, using an electronic CRF. HIV-positive patients were excluded. Follow-up data were recorded at least twice a year. We present the baseline characteristics of 2148 out of 2840 patients enrolled.

Results: Males were 69.6%; age 49.5±14.4; BMI 25.3±3.9; 23.7% were immigrants, mainly from Eastern Europe or Asia. Laboratory features included: mean ALT 57.5±100; 12.6% HBeAg-positive; HBV DNA detectable in 37.2%; HCV or HDV coinfection in 4.4 and 8.8% respectively, alcohol use (>3 drinks/day) in <3%; 45.1% had undergone liver biopsy. Overall, 21% of the patients had cirrhosis, 29% of whom with decompensation. As compared with Italian patients, immigrants were younger (36.8±10.9 vs 53.4±13.1 P<0.001), more frequently HBeAg-positive (26.1% vs 8.4% P<0.001), and anti-HDV-positive (12% vs 7.8%; P<0.02).

Previous antiviral treatment was recorded in 51% of the cases and at the time of enrolment, 49% of the patients were being treated with antivirals.

Among 394 patients with cirrhosis, 12.7% were HBeAg-positive, 19% anti-HDV-positive and 7.9% anti-HCV-positive. At the time of enrolment, 40.1% of cirrhotic patients were not under antiviral treatment.

Conclusions: Chronic HBV infection shows an evolving burden due to the growing cohort of non-Italian patients, who show higher rates of HBeAg or presence of anti-HDV. There are still barriers to access medical care for cirrhotic patients since 40% of them were untreated when first seen in the specialized centers.

Sponsored by the Italian Association for the Study of Liver (AISF)